1. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Issue 10 (26th November 2018) Authors: De Roeck, L.; Michaux, L.; Debackere, K.; Lierman, E.; Vandenberghe, P.; Devos, T. Journal: Hematology Issue: Volume 23:Issue 10(2018) Page Start: 785 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A novel approach for BCR‐ABL1 standardization to improve International Scale estimation. (27th July 2016) Authors: Maes, B.; Bakkus, M.; Boeckx, N.; Boone, E.; Cauwelier, B.; Denys, B.; De Schouwer, P.; Devos, T.; El Housni, H.; Hillen, F.; Jacobs, K.; Lambert, F.; Louagie, H.; Maes, M.‐B.; Meeus, P.; Moreau, E.; Nollet, F.; Peeters, K.; Saussoy, P.; Van Lint, P. Journal: International journal of laboratory hematology Issue: Volume 38:Number 6(2016:Dec.) Page Start: 674 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY. (23rd June 2022) Authors: Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Harrison, C.; Bose, P.; Rampal, R. K.; Palandri, F; Devos, T.; Passamonti, F.; Hobbs, G.; Talpaz, M.; Vannucchi, A.; Kiladjian, J.-J.; Verstovsek, S.; Hoffman, R.; Salama, M. E.; Chen, D.; Taverna, P.; Chang, A.; Colak, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P699: REAL-LIFE OUTCOMES OF PONATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) OR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): 5-YEAR-DATA FROM A BELGIAN REGISTRY. (23rd June 2022) Authors: Devos, T.; Havelange, V.; Theunissen, K.; Meers, S.; Benghiat, F. S.; Gadisseur, A.; Vanstraelen, G.; Vellemans, H.; Bailly, B.; Granacher, N.; Lewalle, P.; De Becker, A.; Van Eygen, K.; Lejeune, M.; Janssen, M.; Triffet, A.; Vrelust, I.; Deeren, D.; Mazure, D.; Beck, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 594 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS. (23rd June 2022) Authors: Kiladjian, J.-J.; Tefferi, A.; Passamonti, F.; Vannucchi, A.; Talpaz, M.; Cervantes, F.; Harrison, C. N.; Mesa, R. A.; Mascarenhas, J.; Schaap, N.; Verstovsek, S.; Devos, T.; Rose, S.; Zhang, J.; Sy, O.; Pardanani, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS. (23rd June 2022) Authors: Harrison, C.; Rampal, R. K.; Gupta, V.; Verstovsek, S.; Talpaz, M.; Kiladjian, J.-J.; Mesa, R.; Kuykendall, A.; Vannucchi, A.; Palandri, F.; Grosicki, S.; Devos, T.; Jourdan, E.; Wondergem, M. J.; Al-Ali, H. K.; Buxhofer-Ausch, V.; Alvarez-Larrán, A.; Akhani, S.; Muñoz-Carerras, R.; Sheykin, Y. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 920 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT. (23rd June 2022) Authors: Mora, B.; Guglielmelli, P.; Kuykendall, A.; Maffioli, M.; Rotunno, G.; Komrokji, R. S.; Palandri, F.; Kiladjian, J.-J.; Iurlo, A.; Auteri, G.; Cattaneo, D.; De Stefano, V.; Salmoiraghi, S.; Devos, T.; Cervantes, F.; Merli, M.; Campagna, A.; Benevolo, G.; Brociner, M.; Albano, F. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 885 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P1361: TREATMENT OF SEVERE STEROID-REFRACTORY ACUTE GVHD WITH MESENCHYMAL STROMAL CELLS: RESULTS OF THE PHASE III RANDOMIZED DOUBLE-BLIND MULTI-CENTER HOVON-113 TRIAL. (23rd June 2022) Authors: Oosten, L.; van Pel, M.; van der Holt, B.; Bach, E.; Cross, M.; Roelofs, H.; Meij, P.; Wieles, B.; Zwaginga, J. J.; Lankester, A.; Veelken, H.; Platzbecker, U.; Sanchez-Guijo, F.; Algeri, M.; Locatelli, F.; Devos, T.; Cornelissen, J.; Niederwieser, D.; Fibbe, W. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Myelofibrosis patients in Belgium: disease characteristics. Issue 2 (April 2015) Authors: Devos, T.; Zachée, P.; Bron, D.; Noens, L.; Droogenbroeck, J. Van; Mineur, P.; Beguin, Y.; Berneman, Z.; Benghiat, F. S.; Kentos, A.; Chatelain, C.; Demuynck, H.; Lemmens, J.; Eygen, K. Van; Theunissen, K.; Trullemans, F.; Pierre, P.; Pluymers, W.; Knoops, L. Journal: Acta clinica belgica Issue: Volume 70:Issue 2(2015) Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study. Issue 2 (April 2014) Authors: Zelis, N.; Devos, T.; Dierickx, D.; Janssens, A.; Raddoux, J.; Verhoef, G.; Delforge, M. Journal: Acta clinica belgica Issue: Volume 69:Issue 2(2014) Page Start: 98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗